Tissue Sodium Quantification in Patients With Primary Aldosteronism: See Sodium to Treat
Study acronym: SSTT
StatusRecruiting
PhaseNot specified
Started2023-12-27
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 6, 2025 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
The study aims to provide quantitative facts on the pathophysiological changes in tissue Na+ content during Na+/K+ redistribution disorders in patients with PA in response to standard therapy. The investigators hypothesize that patients with primary aldosteronism have excessive Na+ storage in the muscle, which can now be quantified non-invasively using 23NaMRI. In analogy to the role of HbA1c as a metabolic long-term marker in diabetes, the quantifiable changes in muscle Na+ content may deliver the data evidence necessary to justify and conduct randomized diagnostic endpoint outcome trials in the future, with the ultimate aim to improve PA detection rate and treatment.
Amendment record
Amended once since 2024-08-21. Every amendment is listed below.
Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-29.
2025-06-04
Amendment Study Status, Conditions, Arms and Interventions, IPDSharing v1
2024-08-21
Original filing
| NCT Number |
NCT06569589 |
| Lead Sponsor |
Jens Titze
Collaborators: Changi General Hospital, Singapore General Hospital, Sengkang General Hospital |
| Conditions |
Hypertension, Primary Aldosteronism, Hypokalemia |
| Enrollment |
80 participants |
| Start Date |
2023-12-27 |
| Primary Completion |
2026-03-31 (estimated) |
| Study Completion |
2026-08-31 (estimated) |
| Updated on ClinicalTrials.gov |
2025-06-06 |